Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20221145 | 0.84 | RIPK1 (0.71) | RAB9AHTTGAAALDH1A1MAPT | |
| SCHEMBL9331393 | 0.84 | RAB9A (0.58) | RAB9AHTTGAAALDH1A1MAPT | |
| SCHEMBL9331375 | 0.84 | RAB9A (0.58) | RAB9AHTTGAAALDH1A1MAPT | |
| SCHEMBL28170723 | 0.83 | RAB9A (0.56) | RAB9AHTTGAAALDH1A1MAPT | |
| SCHEMBL12265802 | 0.82 | POLB (0.57) | RAB9AHDAC6CA1CA2CA7 | |
| SCHEMBL20363334 | 0.82 | RAB9A (0.55) | RAB9AHTTGAAALDH1A1MAPT | |
| SCHEMBL19169577 | 0.82 | RAB9A (0.55) | RAB9AHTTGAAALDH1A1MAPT | |
| SCHEMBL17447491 | 0.82 | RAB9A (0.55) | RAB9AHTTGAAALDH1A1MAPT | |
| SCHEMBL3614049 | 0.81 | NAMPT (0.56) | RAB9AHTTGAAALDH1A1MAPT | |
| SCHEMBL1516186 | 0.81 | RIPK1 (0.71) | RAB9AHDAC6CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-10173980-B2 | Mixed disulfide conjugates of thienopyridine compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-01-08 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20180155289-A1 | MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-06-07 | — | — | US | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110028509-A1 | Sulfonamides | MERCK SERONO SA (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | RAB9A 2417/4885HDAC6 1696/4885CA1 3499/4885 |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | RAB9A 3408/4885HDAC6 2316/4885CA1 3085/4885 |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | RAB9A 1789/4885HDAC6 1870/4885CA1 4865/4885 |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | RAB9A 1550/4885HDAC6 193/4885CA1 4836/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | RAB9A 4069/4885HDAC6 3771/4885CA1 3605/4885 |
| US-10173980-B2 | Mixed disulfide conjugates of thienopyridine compounds and uses thereof | TST, TXN, TXNRD2 | RAB9A 2782/4885HDAC6 281/4885CA1 3057/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | RAB9A 1952/4885HDAC6 1489/4885CA1 2064/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | RAB9A 1456/4885HDAC6 1725/4885CA1 4847/4885 |
| US-20140046043-A1 | C-4\" POSITION SUBSTITUTED MACROLIDE DERIVATIVE | MRPL21, MRPS34, MRPL37 | RAB9A 3158/4885HDAC6 783/4885CA1 4853/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | RAB9A 2417/4885HDAC6 1696/4885CA1 3499/4885 |
| US-20180155289-A1 | MIXED DISULFIDE CONJUGATES OF THIENOPYRIDINE COMPOUNDS AND USES THEREOF | TST, TXN, TXNRD2 | RAB9A 2782/4885HDAC6 281/4885CA1 3057/4885 |
| US-20110028509-A1 | Sulfonamides | CXCR3, CXCR2, CXCR1 | RAB9A 2029/4885HDAC6 888/4885CA1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.